Literature DB >> 17597280

[Can one propose aesthetic surgery to one male or female patient with an hereditary angio-oedema?].

J-L Heusse1, O Claude, L Lantieri.   

Abstract

The hereditary angio-oedema (HAE) is a rare disease characterised by the occurrence of spontaneous or secondary, subcutaneous and submucosal swellings within any part of the body and especially in the upper respiratory tract. Surgery, due to the stress and the oro-tracheal intubation is a high risk situation for severe attack occurrence that may engage the patient life. This explains reluctance for surgeons and anesthesiologists to perform surgical operations in these patients. We think that efficiency of the prophylaxis and the emergency care for acute attacks can allow them to propose to these patients, plastic and aesthetic surgery in optimal security conditions. Androgens represent the main part of HAE prophylaxis treatment but usually cause masculinization in the females. We report this case of a woman, affected by HAE, treated by danazol: Danatrol for long-term prophylaxis who developed a mammary hypotrophy for which she was desirous to correct with breast implant. This surgery provided good morphological results without complication and was enabled to increase the observance of the prophylaxis treatment. Through this case report we lend a practical view of the surgery management of these patients affected by hereditary angio-oedema.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17597280     DOI: 10.1016/j.anplas.2007.05.011

Source DB:  PubMed          Journal:  Ann Chir Plast Esthet        ISSN: 0294-1260            Impact factor:   0.660


  2 in total

Review 1.  Considerations in the management of hereditary angioedema due to C1-INH deficiency in women of childbearing age.

Authors:  Florence Ida Hsu; William Lumry; Marc Riedl; Raffi Tachdjian
Journal:  Allergy Asthma Clin Immunol       Date:  2022-07-13       Impact factor: 3.373

2.  Hereditary angioedema in women.

Authors:  Laurence Bouillet
Journal:  Allergy Asthma Clin Immunol       Date:  2010-07-28       Impact factor: 3.406

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.